Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 324 results for "biocon"

Cancer drugs to cost more on high duty
Hindustan Times

Custom Duty Exemption Withdrawal on Life Saving Drugs Face Flak

The withdrawal of customs duty exemption on imports of life-saving drugs came under criticism today with Biocon chief Kiran Mazumdar-Shaw saying levy of any kind of duty for these medicines does not resonate well with India's affordable healthcare mission. Outlook, 4 hours ago

29 images for biocon

Business Standard, 1 day ago
NDTV Profit, 1 week ago
Business Standard India, 1 week ago, 2 weeks ago
Money Today, 2 weeks ago
Financial Express, 2 weeks ago
Financial Express, 2 weeks ago
Money Control, 2 weeks ago
International Business Times India, 2 weeks ago
NDTV Profit, 2 weeks ago
Business Standard

Biocon Academy ties up with Bits Pilani to offer microbiology courses.

Email this Print Biocon Academy, an initiative of biopharma major Biocon said it is offering a programme in Quality Control Microbiology (QCMB) in collaboration with the Birla Institute of Technology & Science (BITS) Pilani. The exclusive ...
 Smart Investor1 day ago

Customs duty on drugs irrational; patients will suffer: Biocon

Kiran Mazumdar Shaw, CMD, Biocon, calls this to be an irrational commentary from the government’s side, as it will only the end-user—the patient—who will have to pay the increased cost.
 Money Control2 days ago Biocon chief lauds Karnataka govt  Deccan Herald2 days ago Lift regulations on startups, help them flourish: Kiran Mazumdar-Shaw  Yourstory.in1 week ago Biocon's Kiran Mazumdar-Shaw Calls for Lifting of Regulations on Start-Ups  NDTV Profit1 week ago

Biocon Academy with BITS Pilani introduces advancement programme in 'Quality Control Microbiology'

Subject matter experts from Biocon and BITS Pilani faculty to impart real world insights Biocon Academy, a CSR initiative of Asia's leading biotechnology company, has introduced of a new and unique programme in Quality Control Microbiology (QCMB) ...
 Financial Express2 days ago Biocon Academy's unveils career advancement in 'quality control microbiology' with BITS Pilani  PharmaBiz3 days ago

Biocon Academy to offer course in 'Quality Control Microbiology'

Bengaluru, Feb 3 (UNI) Biocon Academy, a CSR initiative of Asia's leading biotechnology company, today announced the introduction of a eight week program in Quality Control Microbiology
 United News of India4 days ago Biocon Academy Introduces First of its Kind Career Advancement Program in 'Quality Control Microbiology' in Collaboration with BITS Pilani  Businessworld India4 days ago Biocon Academy to offer course in Quality Control Microbiology  Newshence.com4 days ago

US API import ban applies only to one drug: Biocon CMD

The US government’s decision to not allow overseas pharmaceutical companies to import active pharmaceutical ingredient (API) applies to only one particular anti retroviral drug and is not a blanket ban, Biocon CMD Kiran Mazumdar-Shaw said.
 Money Control2 days ago Blanket API Import Ban Rumors Panic India  Pharmaceutical Manufacturing Magazine2 days ago

After Murthy, Mazumdar-Shaw says Karnataka supported her Biocon too

BENGALURU: A day after Infosys co-founder N.R.Narayana Murthy said Infosys would not have survived and reached where it is today but for the timely funding support from the Karnataka Government, Biocon founder Kiran Mazumdar-Shaw too narrated a ...
 Economic Times3 days ago

Likely API import ban by US a super protectionist move:Biocon MD

It is not only super protectionist but also not feasible because apart from huge inflation in cost of generation this move will also create huge drug shortage, said Kiran Mazumdar Shaw, CMD of Biocon.
 Money Control3 days ago

Biocon (Q3 FY16): Revenues disappoint, margin in line

Research services revenue increase of ~30% drove 8.7% yoy increase in revenues vs. estimated 13.3%. CMP Rs482, 1-yr Target Rs450, Downside 6.5% Biocon Q3 revenues miss estimates though margins were in line Research services revenue increase of ~30% drove 8.7% ...
 India Infoline1 week ago Biocon gains on reporting 13% rise in Q3 consolidated net profit  Finalaya.com1 week ago BIOCON Q3 NET PROFIT UP 13% AT Rs103 CRORE  Pharmacy Choice1 week ago Biocon ends marginally lower despite growth in Q3 PAT  India Infoline2 weeks ago
Business Standard India

Biocon to conduct oral insulin trials on its own

Biopharma major Biocon Ltd will conduct on its own the next phase of clinical trials of its oral insulin Tregopil with a larger patient pool including in India, as the company expects the drug, after regulatory approvals, would offer it licensing ...
 Smart Investor1 week ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - biocon
Get updated on latest news & your favorite topics right in your inbox!
More     Less